Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015 · The Lancet Oncology · 472 citations
https://doi.org/10.1016/s1470-2045(15)00021-2